Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intermittent Tiotropium in Early Childhood Wheezing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Children at the age of 6 to 35 months.~2. Two to four physician-confirmed episodes of wheeze and/or shortness of breath.~3. Parents/legal representatives with sufficient written and spoken skills in Finnish language.~Exclusion Criteria:~1. Birth before 36th week of gestation.~2. Suspected/diagnosed chronic parenchymal lung disease or a structural airway defect, or a history of thoracotomy with pulmonary resection.~3. A history of congenital or acquired heart disease, including any unstable or life-threatening cardiac arrhythmia.~4. Constipation with a need of regular medication, or a diagnosed/suspected structural defect in the gastrointestinal tract.~5. A history of malignancy, or other significant chronic disorder, disease, or defect.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: f

Study Arms:
- Tiotropium Bromide & Salbutamol (Type: EXPERIMENTAL): Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
- Fluticasone Propionate & Salbutamol (Type: ACTIVE_COMPARATOR): Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
- Salbutamol (Type: ACTIVE_COMPARATOR): Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath

Based on this trial design, predict the completion outcome and termination type (if applicable).